Treating malignant glioma in Chinese patients: Update on temozolomide

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 235-244

  Chang, Liang ^a   Su, Jun ^a   Jia, Xiuzhi ^a,b   Ren, Huan ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Heilongjiang Province   (China)

Author keywords

Chemotherapy; Efficacy; Malignant glioma; People's Republic of China; Side effect; Temozolomide

Indexed keywords

EID: 84894242049     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S41336     Document Type: Review

References (71)

1. Zhou LF, Wang RZ, Bao SD, et al. [Chinese guideline for diagnosis and treatment on central nervous system tumors]. Zhonghua Yi Xue Za Zhi. 2012;92:2309-2313. Chinese.
2. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10:319-331.
3. Yin L, Zhang L. Correlation between MRI findings and histological diagnosis of brainstem glioma. Can J Neurol Sci. 2013;40:348-354.
4. Di Stefano AL, Enciso-Mora V, Marie Y, et al. Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. Neuro Oncol. 2013;15:542-547.
5. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;100:2235-2241.
6. Yang P, Wang Y, Peng X, et al. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol. 2013;113:259-266.
7. Chen C, Xu T, Lu Y, et al. The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol. 2013;20:223-230.
8. Strik HM, Marosi C, Kaina B, et al. Temozolomide dosing regimens for glioma patients. Curr Neurol Neurosci Rep. 2012;12:286-293.
9. Wu JS, Zhang J, Zhuang DX, et al. Current status of cerebral glioma surgery in China. Chin Med J (Engl). 2011;124:2569-2577.
10. Qiu TM, Yao CJ, Wu JS, et al. Clinical experience of 3T intraoperative magnetic resonance imaging integrated neurosurgical suite in Shanghai Huashan Hospital. Chin Med J (Engl). 2012;125:4328-4333.
11. Wang J, Liu X, Ba YM, et al. Effect of sonographically guided cerebral glioma surgery on survival time. J Ultrasound Med. 2012;31: 757-762.
12. Wu JS, Gong X, Song Y, et al. 142 3.0T iMRI guided resection in cerebral glioma surgery: interim analysis of a prospective, randomized, triple-blind, parallel-controlled trial. Neurosurgery. 2013;60 Suppl:167.
13. Pichlmeier U, Bink A, Schackert G, et al. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol. 2008;10:1025-1534.
14. Wang L, Tu Q, Zhou W, et al. [Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011;36:1106-1110. Chinese.
15. Zhai X, Wang J, Zhang J, et al. [Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas]. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32:255-257. Chinese.
16. Ma X, Lv Y, Liu J, et al. Survival analysis of 205 patients with glioblastoma multiforme: clinical characteristics, treatment and prognosis in China. J Clin Neurosci. 2009;16:1595-1608.
17. Wang ZG, Yang WD, Yang SY, et al. [A clinical effect of temozolomide in patients with malignant glioma]. Journal of Tianjin Medical University. 2008;14:148-151. Chinese.
18. Sai K, Yang QY, Shen D, et al. Chemotherapy for gliomas in mainland China: an overview. Oncol Lett. 2013,5:1448-1452.
19. Wang Y, Chen X, Zhang Z, et al. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. Neurosurg Rev. 2014,37: 73-78.
20. Yao CX, Zhang SP, Chen B, et al. [Clinical effect of intensity modulated radiation therapy combined with concomitant and adjuvant temozolomide in the treatment for malignant glioma]. China Cancer J. 2013;22: 238-240. Chinese.
21. Brandes AA, Bartolotti M, Franceschi E. Second surgery for recurrent glioblastoma: advantages and pitfalls. Expert Rev Anticancer Ther. 2013;13:583-587.
22. Zhou LF, Yao Y, Yang S et al. The Stupp regimen preceded by early post-surgery temozolomide versus the Stupp regimen alone in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol. 2013;31 no. 15. Abstract 2022.
23. Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S. A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer. 2005;104:2798-2806.
24. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
25. Yan YI, Tang WY, Deng ZX, et al. [Efficacy of temozolomide in treatment of recurrent glioma]. Cancer Research on Prevention and Treatment. 2007;17:1359-1364. Chinese.
26. Reardon DA, Vredenburgh JJ, Desjardins A, et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol. 2011;101:57-66.
27. Wang W. [The treatment of elder patient with glioblastoma: a case report]. People's Military Surgeon. 2008;6:369-370. Chinese.
28. Tianjin Tasly Group Co [homepage on the Internet]. China: association of temozolomide. Online Resources [updated August 16, 2012; cited August 9, 2013]. Available from: http://www.tasly.com/. Accessed August 29, 2013.
29. Hong WQ, Zheng G, Wang FS, et al. [Advances of temozolomide in the treatment of malignant gliomas]. Chinese Journal of Neuro-oncology. 2008;6:260-264. Chinese.
30. Shen D, Yang QY, Chen ZP. [Advances in the chemotherapy of malignant gliomas with temozolomide]. Chinese Journal of Neuro-oncology. 2012;4:271-276. Chinese.
31. Wang X, Chen JX, Liu YH, et al. Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase. Neurol Sci. 2013;34:1421-1428.
32. Boulton S, Pemberton LC, Porteous JK, et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer. 1995;72:849-856.
33. Wu Z, Chan CL, Eastman A, Bresnick E. Expression of human O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compounds. Mol Carcinog. 1991;4:482-488.
34. Zeng X, Yang S. Clinical observation in chemotherapy with temozolomide alone in postoperative malignant primary cerebral glioma. Mod J Neurol Neurosurg. 2003;3:270-273.
35. Qian ZZ, Wang HQ, Liu XM, et al. [A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma]. Zhonghua Yi Xue Za Zhi. 2009;89:2059-2062. Chinese.
36. Ji YM, Xin L, Yang GK, et al. Comparison of clinical effect between temozolomide and nimustine in patients with malignant gliomas]. Chinese Journal of Cancer Prevention and Treatment. 2007;14: 1021-1022. Chinese.
37. Sun J, Yang XJ, Yang SY. [Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma]. Zhonghua Yi Xue Za Zhi. 2013;93:165-168. Chinese.
38. Glas M, Happold C, Rieger J, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol. 2009;27:1257-1261.
39. Happold C, Roth P, Wick W, et al. ACNU-based chemotherapy for re-current glioma in the temozolomide era. J Neurooncol. 2009;92: 45-48.
40. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874-5880.
41. Yin AA, Zhang LH, Cheng JX, et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis. PLoS One. 2013;8:e74242.
42. Hart MG, Grant R, Garside R, et al. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2008;4:CD007415.
43. Liang H, Dong SL. [Effectiveness and safety of postoperative radiotherapy plus temozolomide for treating brain malignant glioma in China: a meta-analysis]. Modern Oncology. 2010;18:2345-2348. Chinese.
44. Wang YW, Yin CL, Zhang ZY, et al. [Meta-analysis of temozolomide for high grade gliomas]. J Shandong University. 2012;50:80-83. Chinese.
45. Zhao HX, Gao LM, Feng W, et al. [Effect of temozolomide plus radiotherapy in the treatment of glioblastoma]. Hainan Medical Journal. 2012;23:1-4. Chinese.
46. Xiao PX, Lin K, Chao SH. [Radiotherapy concomitant with temozolomide for glioblastoma multiforme]. Chinese Journal of Neuro-oncology. 2005;4:290-295. Chinese.
47. Jin WW, Zhang HY, Wang YT, et al. [The clinical observation of temozolomide combined with intensity-modulated radiotherapy in the treatment of malignant glioma with positive MGMT]. J Bengbu Med Coll. 2013;38:56-58. Chinese.
48. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
49. Katoh M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev. 2007;3: 30-38.
50. Xie Q, Xi G, Gong Y, et al. Protease activated receptor-1 and brain edema formation in glioma models. Acta Neurochir Suppl. 2013;118: 191-194.
51. Hutchinson L. Targeted therapies: glioma - it's all in the site occupancy. Nat Rev Clin Oncol. 2012;9:308.
52. Yang QY, Shen D, Sai K, et al. [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. Zhonghua Zhong Liu Za Zhi. 2011;33:232-235. Chinese.
53. Chen XH, Zhou YX, Sun CM, et al. Combined modality therapy of recurrent glioma. J Clin Neurosurg. 2012:9:88-90.
54. Yang QY, Guo CC, Sai K, et al. [Phase II trial of temozolomide plus interferon-β in recurrent malignant glioma patients]. Chinese Journal of Neuro-oncology. 2012;10:234-239. Chinese.
55. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13-47.
56. Dario A, Tomei G. The safety of temozolomide in patients with malignant glioma. Curr Drug Saf. 2006;1:205-222.
57. Minniti G, Salvati M, Arcella A, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol. 2011;102: 311-316.
58. Gerstner ER, Eichler AF, Plotkin SR, et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011;103: 325-332.
59. Zhou BY, Mao Q, Wang P, et al. [The adverse effects analysis of temozolomide in glioma chemotherapy]. Chinese Journal of Neuro-oncology. 2012;10:14-18. Chinese.
60. Levati L, Ruffini F, Muzi A, et al. Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-kappaB. Int J Oncol. 2011;38:241-247.
61. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142-148.
62. Li G, Yang QY, Guo Y, et al. [Extended use of temozolomide for glioma patients based on MGMT expression pattern: experience of 32 cases]. Chinese Journal of Neuro-oncology. 2012;10:158-165. Chinese.
63. Wang G, Xiao H, Guo LY, et al. [Radiotherapy combined with temozolomide treatment for glioblastoma multiforme: a meta-analysis]. Tumor. 2010;30:1056-1065. Chinese.
64. Geiger H, Schleimer D, Nattamai KJ, et al. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood. 2006;107:3010-3011.
65. Grewal J, Dellinger CA, Yung WK, et al. Fatal reactivation of hepatitis B with temozolomide. N Engl J Med. 2007;356:1591-1592.
66. Goldbecker A, Tryc AB, Raab P, et al. Hepatic encephalopathy after treatment with temozolomide. J Neurooncol. 2011;103:163-166.
67. Klepper B, Pauker D. Medicare's drug plan: huge price disparities for common cancer drugs. Community Oncol. 2006;3:753-5511.
68. Crott R. The economics of temozolomide in brain cancer. Expert Opin Pharmacother. 2007;8:1923-1929.
69. Wu B, Miao Y, Bai Y, et al. Subgroup economic analysis for glioblastoma in a health resource-limited setting. PLoS One. 2012;7:e34588.
70. Wang Q, Wang NY, Sheng HM, et al. [Clinical observation in temozolomide combined with radiotherapy in treatment of postoperative malignant glioma]. Chin J Cancer Prev Treat. 2008;15:843-845. Chinese.
71. Fu H, Wan LL, Yang L, et al. [Clinical study of temozolomide combined with radiotherapy in treatment of postoperative malignant glioma]. Chinese General Practice. 2011;14:1556-1558. Chinese.